Search results
Diana Gorog
Research Area(s) / Expertise:
Job title: Cardiologist and Clinical Lead for Non-cancer Research
Author
Khaled Al-Shaibi
Research Area(s) / Expertise:
Author
Expertise
InterventionHeart FailureChronic Heart Failure ManagementCoronary InterventionsGuidelines & StatementsHypertensionCardiac AmyloidosisGenderMI/ACSCardiomyopathies and Cardiac AmyloidosisElectrophysiology & ArrhythmiaHFrEF Pharmacological ManagementPacing, Defibrillators & Cardiac Resynchronisation TherapyHFpEF Pharmacological ManagementStructural InterventionAtrial FibrillationHFmrEF Pharmacological ManagementAnticoagulationPrevention & Chronic ConditionsDemographic
Junaid Zaman
Research Area(s) / Expertise:
Job title: Assistant Professor of Clinical Medicine
Author
Stéphane G Carlier
Job title: Professor of Cardiology, Université de Mons (UMons), Mons, Belgium
Author
Martha Gulati
Research Area(s) / Expertise:
Author
Expertise
InterventionHeart FailureChronic Heart Failure ManagementCoronary InterventionsGuidelines & StatementsHypertensionCardiac AmyloidosisGenderMI/ACSCardiomyopathies and Cardiac AmyloidosisElectrophysiology & ArrhythmiaHFrEF Pharmacological ManagementPacing, Defibrillators & Cardiac Resynchronisation TherapyHFpEF Pharmacological ManagementStructural InterventionAtrial FibrillationHFmrEF Pharmacological ManagementAnticoagulationPrevention & Chronic ConditionsDemographic
Marcelo F Di Carli
Research Area(s) / Expertise:
Author
Expertise
InterventionHeart FailureChronic Heart Failure ManagementCoronary InterventionsGuidelines & StatementsHypertensionCardiac AmyloidosisGenderMI/ACSCardiomyopathies and Cardiac AmyloidosisElectrophysiology & ArrhythmiaHFrEF Pharmacological ManagementPacing, Defibrillators & Cardiac Resynchronisation TherapyHFpEF Pharmacological ManagementStructural InterventionAtrial FibrillationHFmrEF Pharmacological ManagementAnticoagulationPrevention & Chronic ConditionsDemographic
Added:
6 months ago
Source:
Radcliffe Cardiology
New analyses from the ATTRibute-CM trial show that the transthyretin (TTR) stabiliser acoramidis provides consistent clinical benefits in patients with both wild-type (ATTRwt-CM) and variant (ATTRv-CM) transthyretin amyloid cardiomyopathy.1 The findings include data from the main 30-month trial and its ongoing 42-month open-label extension (OLE).Acoramidis is an orally administered, small…
View more
Neil T Srinivasan
Research Area(s) / Expertise:
Author
Expertise
InterventionHeart FailureChronic Heart Failure ManagementCoronary InterventionsGuidelines & StatementsHypertensionCardiac AmyloidosisGenderMI/ACSCardiomyopathies and Cardiac AmyloidosisElectrophysiology & ArrhythmiaHFrEF Pharmacological ManagementPacing, Defibrillators & Cardiac Resynchronisation TherapyHFpEF Pharmacological ManagementStructural InterventionAtrial FibrillationHFmrEF Pharmacological ManagementAnticoagulationPrevention & Chronic ConditionsDemographic
Aneil Malhotra
Research Area(s) / Expertise:
Author
Expertise
InterventionHeart FailureChronic Heart Failure ManagementCoronary InterventionsGuidelines & StatementsHypertensionCardiac AmyloidosisGenderMI/ACSCardiomyopathies and Cardiac AmyloidosisElectrophysiology & ArrhythmiaHFrEF Pharmacological ManagementPacing, Defibrillators & Cardiac Resynchronisation TherapyHFpEF Pharmacological ManagementStructural InterventionAtrial FibrillationHFmrEF Pharmacological ManagementAnticoagulationPrevention & Chronic ConditionsDemographic
Hariharan Raju
Author